Alvotech (ALVO) Q4 2024 earnings summary

Executive summary

• Achieved total revenues of $492 million in 2024, a 427% year-over-year increase, with product revenues of $273 million and milestone revenues of $216 million.

• Adjusted EBITDA turned positive at $108 million, a swing from a $291 million loss in 2023, driven by new product launches and manufacturing efficiencies.

• Successful launches of biosimilars to HUMIRA® (SIMLANDI®) in the US and STELARA® (SELARSDI®) internationally, with strong formulary positions and rapid market uptake.

• Strategic acquisition of Xbrane R&D in Sweden, adding a Cimzia biosimilar to the pipeline and expanding R&D capabilities.

• Raised over $300 million in capital in 2024, including $150 million in new equity and full refinancing of short-term debt.

Financial highlights

• Product revenues grew 462% year-over-year to $273 million; licensing and other revenues increased to $219 million.

• Gross profit improved to $308 million from a loss of $62 million in 2023; gross margin rose to 63% from -67%.

• Product margin improved to 33% in 2024, up from -220% in 2023, with Q4 product margins rising to 45%.

• Net debt stood at $1.018 billion with $51 million cash on hand at year-end.

• 301.8 million shares outstanding at year-end, with potential dilution from warrants and RSUs.

Outlook and guidance

• 2025 revenue guidance: $570–$670 million, with product revenue of $340–410 million and milestone revenues of $230–260 million.

• Product margin expected at 38–41% and gross margin at 63–64% for 2025.

• Adjusted EBITDA guidance for 2025: $180–$260 million; company expects to be free cash flow positive in 2025.

• Three new biosimilar launches planned globally in 2025, including AVT03, AVT05, and AVT06, with approvals anticipated in Q4.

• Long-term goal: $1.5 billion revenue and 40–45% EBITDA margin by 2028.